Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-72 (IGHV3-72) is a protein-coding gene that encodes the variable region of the heavy chain of immunoglobulins (antibodies)[1][6][8]. This region forms part of the antigen-binding site of antibodies, which are crucial for the recognition phase of the humoral immune response[1][6]. The variable regions from heavy (e.g., IGHV3-72) and light chains together enable an antibody to bind with high specificity to a particular antigen[1][6][8]. Antigen engagement triggers B cell activation and differentiation into plasma cells that secrete immunoglobulins, mediating antigen clearance[1][8]. IGHV3-72, like other IGHV genes, undergoes genetic recombination and somatic hypermutation to promote antibody diversity. IGHV3-72 is one of many allelic members of the IGHV gene family, contributing to the genetic and functional diversity of the human antibody repertoire[2][4]. Polymorphisms within IGHV genes are linked to differences in immune responses, and certain IGHV alleles/families may be associated with susceptibility or resistance to particular diseases and reactions, although IGHV3-72 itself is not a direct therapeutic target[4]. Diseases possibly associated or studied in connection with IGHV3-72 include toxic pneumonitis and isolated growth hormone deficiency, mainly as part of broader antibody and immune system studies[1]. IGHV3-72 is a genetic element and not a receptor or direct drug target—therapeutic interventions target the antibodies or B cells utilizing this region, not the IGHV3-72 gene specifically[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-72 (IGHV3-72).